NextCure (NXTC) Interest & Investment Income (2019 - 2026)
NextCure (NXTC) posted quarterly Interest & Investment Income of -$23000.0 for Q1 2026, down 475.0% year-over-year from $6133.3 in Q1 2025, and down 675.0% quarter-over-quarter from $4000.0 in Q4 2025.
NextCure (NXTC) Interest & Investment Income (2019 - 2026) Analysis & Trends
NextCure's Interest & Investment Income history runs 8 years deep, the most recent figure standing at -$23000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 475.0% year-over-year to -$23000.0; the TTM figure through Mar 2026 stood at -$2000.0 (down 101.1% YoY), while the FY2025 annual figure was $17000.0, down 92.48% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$23000.0, down from $4000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $902000.0 in Q4 2022, with the low at -$1.5 million in Q1 2022.
- The 5-year median for Interest & Investment Income is $4000.0 (2025), against an average of $38882.4.
- The sharpest annual moves came in 2023 and 2026: Interest & Investment Income jumped 675.0% in 2023, then tumbled 475.0% in 2026.
- NextCure's Interest & Investment Income stood at $902000.0 in 2022, then slumped by 57.76% to $381000.0 in 2023, then slumped by 118.9% to -$72000.0 in 2024, then jumped by 105.56% to $4000.0 in 2025, then plunged by 675.0% to -$23000.0 in 2026.
- Business Quant data shows NXTC's Interest & Investment Income at -$23000.0 in Q1 2026, $4000.0 in Q4 2025, and $24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -23,000.00 |
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 381,000.00 |
| Sep 30, 2023 | 322,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Mar 31, 2023 | 691,000.00 |
| Dec 31, 2022 | 902,000.00 |
| Sep 30, 2022 | -56,000.00 |
| Jun 30, 2022 | -141,000.00 |
| Mar 31, 2022 | -1.54 Mn |
| Dec 31, 2021 | -534,000.00 |
| Sep 30, 2021 | 66,000.00 |